ETS_Hires_VP, Sales, Eric

Emerging Therapy Solutions® Hires Cell and Gene Therapy Consultant, Eric Trepanier as Vice President, Sales.

Emerging Therapy Solutions expands team as cell and gene therapy market continues to see growth.

BLOOMINGTON, Minn., April 20, 2022 – Emerging Therapy Solutions® (ETS) announces it has hired Eric Trepanier formerly of Dirt Road Consultants and Premera as its new Vice President of Sales.

Trepanier has over twenty years of experience in the healthcare industry in pharmaceutical sales and provider network contract negotiation, with the last almost nine years focused on the cell and gene therapy arena.

“We are excited to leverage Eric’s extensive experience in the cell and gene market, along with his focus on cost containment and savings solutions, and his relationships and understanding of the complex insurance and reinsurance markets to benefit Emerging Therapy Solutions clients,” said David J. McLean, Ph.D., Co-founder and CEO, ETS. “As we continue to expand our ETS client services and offerings, we are pleased to grow our team with experienced resources to effectively support our customers and their teams.”

Eric’s deep knowledge of cell and gene therapy and health insurance stems from his years as a Senior Internal Consultant with Seattle-based Premera Blue Cross, where he led the development of Premera’s multi-pronged cost containment solutions for Cell and Gene Therapy, molecular diagnostics, and opioid treatments. Prior to his consulting role, Eric spent several years as a provider network executive for Premera. Most recently, he provided seasoned commercialization consulting services to manufacturers and investors in the cell and gene therapy arena through his business Dirt Road Consultants, Inc.

“I am really pleased to be part of this industry-leading company,” shared Trepanier. “I’m looking forward to continuing to help companies in the cell and gene therapy space as they identify their needs and look for the best solutions.”

Known for its industry expertise in cell and gene therapies, ETS is the premier end-to-end solution provider to help payers manage the immense cost, high risk and intricate processes associated with treating rare, complex and costly medical conditions. ETS services include pipeline monitoring, expert clinical and medical coverage content and education; network management and access to ETS negotiated rates at medical center Programs of Excellence; accurate and timely claims services; and actuarial data analytics and reporting. ETS also helps payers with the plan design, analytics, clinical data modeling, and policy design related to high-cost conditions.

About Emerging Therapy Solutions

Emerging Therapy Solutions® (ETS) helps healthcare payers – including reinsurance and stop-loss payers, health plans and self-funded employers – manage the risks associated with high-cost therapies for rare and complex conditions. We offer a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies.

For more information about ETS or media inquiries, please contact:

Sara Hakanson
Vice President, Marketing
Emerging Therapy Solutions 


We are ready to help you manage your risk.

Contact Us